<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35434687</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Persistent symptoms after the first wave of COVID-19 in relation to SARS-CoV-2 serology and experience of acute symptoms: A nested survey in a population-based cohort.</ArticleTitle><Pagination><StartPage>100363</StartPage><MedlinePgn>100363</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100363</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2022.100363</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Many patients report persistent symptoms after COVID-19. Our aim was to determine whether some of these symptoms were more associated with past SARS-CoV-2 infection compared to other conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This prospective survey was nested in CONSTANCES, a randomly selected French population-based cohort, started in 2012. All participants being followed-up by internet completed 2 questionnaires during the first wave of the pandemic focusing on the acute symptoms of their COVID-19-like illness. Serological tests for SARS-CoV-2 were then performed (May-Nov 2020). Between December 2020 and January 2021, participants completed a third questionnaire about symptoms that had lasted more than 2 months. Participants were classified into four groups according to both European Center for Diseases Control (ECDC) criteria for COVID-19 (ECDC+ or ECDC-) and serological SARS-CoV-2 test results (Sero+ or Sero-). To compare the risk of each persistent symptom among the groups, logistic regression models were adjusted for age, sex, educational level, comorbidities, and the number of acute symptoms declared during the first wave of the epidemic. A mediation analysis was performed to estimate the direct effect of the infection on persistent symptoms and its indirect effect via the initial clinical presentation.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">The analysis was performed in 25,910 participants. There was a higher risk of persistent dysgeusia/anosmia, dyspnea and asthenia in the ECDC+/Sero+ group than in the ECDC+/Sero- group (OR: 6.83 [4.47-10.42], 1.69 [1.07-2.6] and 1.48 [1.05-2.07], respectively). Abdominal pain, sensory symptoms or sleep disorders were at lower risk in the ECDC+/Sero+ group than in the ECDC+/Sero- group (0.51 [0.24-0.96], 0.40 [0.16-0.85], and 0.69 [0.49-0.95], respectively). The mediation analysis revealed that the association of the serological test results with each symptom was mainly mediated by ECDC symptoms (proportion mediated range 50-107%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">A greater risk of persistent dysgeusia/anosmia, dyspnea and asthenia was observed in SARS-CoV-2 infected people. The initial clinical presentation substantially drives the association of positive serological test results with persistent symptoms.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">French National Research Agency.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robineau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA2694, University Lille, Centre Hospitalier de Tourcoing, Centre hospitalier Gustave Dron, Rue du pr&#xe9;sident Ren&#xe9; Coty, Tourcoing 59200, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiernik</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Population-based epidemiological cohorts. UMS 11, Paris Saclay University, Versailles St Quentin University, Universit&#xe9; de Paris, INSERM, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), Universit&#xe9; de Paris, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, UMR_S1266, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit&#xe9; des Virus Emergents, UVE: Aix Marseille University, IRD 190, Inserm 1207, IHU M&#xe9;diterran&#xe9;e Infection, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ninove</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit&#xe9; des Virus Emergents, UVE: Aix Marseille University, IRD 190, Inserm 1207, IHU M&#xe9;diterran&#xe9;e Infection, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanch&#xe9;</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribet</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Population-based epidemiological cohorts. UMS 11, Paris Saclay University, Versailles St Quentin University, Universit&#xe9; de Paris, INSERM, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kab</LastName><ForeName>Sofiane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Population-based epidemiological cohorts. UMS 11, Paris Saclay University, Versailles St Quentin University, Universit&#xe9; de Paris, INSERM, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Population-based epidemiological cohorts. UMS 11, Paris Saclay University, Versailles St Quentin University, Universit&#xe9; de Paris, INSERM, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severi</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CESP UMR1018, Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touvier</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center - University of Paris (CRESS), Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zins</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Population-based epidemiological cohorts. UMS 11, Paris Saclay University, Versailles St Quentin University, Universit&#xe9; de Paris, INSERM, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de sant&#xe9; publique, H&#xf4;pital Saint-Antoine, APHP, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Constances</Keyword><Keyword MajorTopicYN="N">Long-covid</Keyword><Keyword MajorTopicYN="N">Persistent symptoms</Keyword><Keyword MajorTopicYN="N">Populationbased study</Keyword><Keyword MajorTopicYN="N">Post-covid condition</Keyword><Keyword MajorTopicYN="N">Post-infectious symptoms</Keyword></KeywordList><CoiStatement>OR reports personal fees and non-financial support from ViiV healthcare, Gilead, MSD. CL reports personal fees and non-financial support from Boehringer Ingelheim, Janssen-Cilag, Lundbeck and Otsuka Pharmaceutical, outside the submitted work. The other authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35434687</ArticleId><ArticleId IdType="pmc">PMC9005155</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2022.100363</ArticleId><ArticleId IdType="pii">S2666-7762(22)00056-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med. 2021;174:723&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1792. published online Nov 30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I. Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting. Ann Intern Med. 2021;174:1252&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280535</ArticleId><ArticleId IdType="pubmed">34224254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanga V, Chevinsky JR, Dimitrov LV, et al. Long-term symptoms among adults tested for SARS-CoV-2 - United States. MMWR Morb Mortal Wkly Rep. 2021;70:1235&#x2013;1241. January 2020-April 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Riveros C, Clepier B, et al. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin Infect Dis. 2021:ciab352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: What do we know about &#x2018;long covid&#x2019;? BMJ. 2020;370:m2815.</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zins M, Goldberg M, team CONSTANCES. The French CONSTANCES population-based cohort: design, inclusion and follow-up. Eur J Epidemiol. 2015;30:1317&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690834</ArticleId><ArticleId IdType="pubmed">26520638</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrat F, de Lamballerie X, Rahib D, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol. 2021;50:1458&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344948</ArticleId><ArticleId IdType="pubmed">34293141</ArticleId></ArticleIdList></Reference><Reference><Citation>Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition. Accessed 4 April 2021.</Citation></Reference><Reference><Citation>Ghosn J, Piroth L, Epaulard O, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021;27 1041.e1-e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8107834</ArticleId><ArticleId IdType="pubmed">34125067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 doi: 10.1038/s41591-021-01292-y. Published online March 10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;3:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">1576220</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics. 1992;48:479&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637973</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J. Direct and indirect effects. Proceedings of the Seventeenth conference on Uncertainty in artificial intelligence; San Francisco, CA, USA; Morgan Kaufmann Publishers Inc.; 2001. pp. 411&#x2013;420.</Citation></Reference><Reference><Citation>Valeri L, VanderWeele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18:137&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659198</ArticleId><ArticleId IdType="pubmed">23379553</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010;172:1339&#x2013;1348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998205</ArticleId><ArticleId IdType="pubmed">21036955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00211-5. Published online May 10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 doi: 10.1038/s41591-021-01433-3. Published online June 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Hingrat Q, Bouzid D, Choquet C, et al. Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France. Influenza Other Respir Viruses. 2021;15:425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189235</ArticleId><ArticleId IdType="pubmed">33817971</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa JD, Brennan PM, Theodoratou E, et al. Distinguishing between direct and indirect consequences of covid-19. BMJ. 2020;369:m2377.</Citation><ArticleIdList><ArticleId IdType="pubmed">32540857</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Wiernik E, Robineau O, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among french adults during the COVID-19 pandemic. JAMA Intern Med. 2021 doi: 10.1001/jamainternmed.2021.6454. Published online Nov 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiology. 2021;6:116&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489396</ArticleId><ArticleId IdType="pubmed">32915194</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020 doi: 10.7326/M20-5926. Published online Dec 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 doi: 10.1001/jama.2021.5612. Published online April 7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-19. Nature. 2021:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>